Steven Kenneth Libutti MD
Endocrine, Surgical Oncology (Other than Breast)
Director, Rutgers Cancer Institute of New Jersey, Vice Chancellor Cancer Programs, Rutgers Biomedical and Health Sciences, Senior Vice President Oncology Services, RWJBarnabas Health
Join to View Full Profile
165 Somerset StreetNew Brunswick, NJ 08901
Dr. Libutti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Endocrine Surgery, 1995 - 1996
New York Presbyterian Hospital (Columbia Campus)Residency, Surgery, 1990 - 1995
Columbia University Vagelos College of Physicians and SurgeonsClass of 1990, MD, Alpha Omega Alpha
Harvard UniversityAB, Biology, Magna Cum Laude, 1982 - 1986
Certifications & Licensure
NJ State Medical License 2017 - 2027
NY State Medical License 1992 - 2027
American Board of Surgery Surgery
Awards, Honors, & Recognition
- PheoPara Alliance Science Award 2012
- America's Top Doctors 2010-2013
- Top Doctors New York Metro Area 2010-2013
Clinical Trials
- PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy Start of enrollment: 1998 Oct 01
- Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer Start of enrollment: 1999 Aug 01
- Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene Start of enrollment: 2003 Sep 01
Publications & Presentations
PubMed
- Social Vulnerability Hinders Clinical Trial Participation in Gastrointestinal Cancer Surgery Patients.Shruthi R Perati, Sana M Mohayya, Henry A Pitt, Ernie Shippey, Howard S Hochster
Annals of Surgery. 2025-07-21 - 2 citationsWorldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.Wafik S El-Deiry, Catherine Bresson, Fanny Wunder, Benedito A Carneiro, Don S Dizon
Oncotarget. 2025-03-12 - In Memoriam: Remembering Adam Berger, MD-Colleague, Mentor, Friend.H Richard Alexander, Steven K Libutti, Madalyn Neuwirth
Annals of Surgical Oncology. 2024-12-11
Journal Articles
- Comparison of Bethesda Cytopathology Classification to Surgical Pathology Across Racial‐Ethnic GroupsBradley A Schiff, Steven K Libutti, Thomas J Ow, Richard V Smith, Juan Lin, Vikas Mehta, Amanda M Laird, Head & Neck
- Minimally Invasive Surgery for Pancreatic Neuroendocrine Tumors Results in Shorter Length of StayAmanda M Laird, John C Mcauliffe, Steven K Libutti, Journal of The American College of Surgeons
- Interferon Alpha Triggers Autoimmune Thyroid Diseases via Lysosomal-Dependent Degradation of ThyroglobulinSteven K Libutti, Yaron Tomer, The Journal of Clinical Endocrinology and Metabolism
Authored Content
- My Favorite Sessions from AACR's 2021 Virtual MeetingApril 2021
- Minimally Invasive Surgery for Pancreatic Neuroendocrine Tumors Results in Shorter Length of StayOctober 2018
- Surface-Modified Shortwave-Infrared-Emitting Nanophotonic Reporters for Gene-Therapy ApplicationsApril 2018
Press Mentions
National Breast Cancer Expert to Lead Breast Surgery Program at Rutgers Cancer Institute and RWJBarnabas Health Southern RegionJanuary 12th, 2026- Landmark Data from Rutgers Cancer Institute and RWJBarnabas Health Show Long-Term Complete Responses of T Cell Therapies for HPV-Related CancersNovember 7th, 2025
- 6 Significant Cancer Hospitals on the HorizonJuly 16th, 2025
Grant Support
- Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer TumorsUNIV OF NORTH CAROLINA CHAPEL HILL2021–2026
- Personalized Modeling of CAR-T Cell Immunotherapy Using iPSC-Derived Effectors and Patient- Derived Tumor OrganoidsRUTGERS BIOMEDICAL AND HEALTH SCIENCES1997–2026
- Personalized Modeling of CAR-T Cell Immunotherapy Using iPSC-Derived Effectors and Patient- Derived Tumor OrganoidsRUTGERS BIOMEDICAL AND HEALTH SCIENCES1997–2026
- Personalized Modeling of CAR-T Cell Immunotherapy Using iPSC-Derived Effectors and Patient- Derived Tumor OrganoidsRUTGERS BIOMEDICAL AND HEALTH SCIENCES1997–2026
- Designing a transcriptome-based, targeted theranostic platform for prostate cancerRUTGERS BIOMEDICAL AND HEALTH SCIENCES2020–2025
Professional Memberships
- Member
- Member
- Member
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
